Company Overview and News

 
Board of Continental Securities appoints company secretary

2016-12-20 indiainfoline
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

 
Carlisle Companies is Oversold

2016-01-07 nasdaq
Join the NASDAQ Community today and get free, instant access to portfolios, stock ratings, real-time alerts, and more!

 
3M Amicably Settles Patent Lawsuit Against Zirkonzahn

2016-01-06 zacks
3M Company (MMM) recently amicably settled its patent infringement lawsuit against Zirkonzahn filed in D??sseldorf, Germany.

 
Honeywell (HON) Remains Well Poised for Long-Term Growth

2016-01-04 zacks
On Jan 4, Zacks Investment Research updated the research report on industrial goods manufacturer Honeywell International Inc. (HON).

 
WELLS FARGO FUNDS TRUST Form N-Q

2015-12-30 sec.gov
Form N-Q       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM N-Q     QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY Investment Company Act file number: 811-09253     Wells Fargo Funds Trust (Exact name of registrant as specified in charter)     525 Market Street, 12th Floor, San Francisco, CA 94105 (Address of principal executive offices) (Zip code)     C.

 
CARLISLE COMPANIES INC Form EX-99.1

2015-12-15 sec.gov
Exhibit 99.1   PRESS RELEASE   12/11/15   D. Christian Koch To Be Named Carlisle Companies CEO Effective January 1, 2016; David A. Roberts Continues as Chairman   CHARLOTTE, NORTH CAROLINA, December 11, 2015 - Carlisle Companies Incorporated (NYSE:CSL) announced today that the Company’s Board of Directors has further implemented its ongoing succession plan and appointed D. Christian Koch (“Chris”) Chief Executive Officer and a member of the Board of Directors, both effective January 1, 2016.

 
CARLISLE COMPANIES INC Form EX-3.1

2015-12-15 sec.gov
Exhibit 3.1   AMENDED AND RESTATED BYLAWS OF CARLISLE COMPANIES INCORPORATED   ARTICLE I MEETINGS OF STOCKHODLERS   Section 1.01.  Annual Meetings.  The annual meeting of the stockholders of CARLISLE COMPANIES INCORPORATED (the “Corporation”) shall be held on such date and at such time and place as will be designated from time to time by the Board of Directors (the “Board”) and stated in the notice of the meeting.

 
CARLISLE COMPANIES INC Form 8-K

2015-12-15 sec.gov
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported):  December 9, 2015     CARLISLE COMPANIES INCORPORATED (Exact name of registrant as specified in its charter)     Delaware (State or other jurisdiction of incorporation)   1-9278 (Commission File Number)   31-1168055 (IRS Employer Identification No.

 
VALUE LINE CENTURION FUND INC Form EX-99.CERT

2015-12-01 sec.gov
  EXHIBIT 99.CERT   CERTIFICATIONS   I, Mitchell E. Appel, President of Value Line Centurion Fund, Inc. certify that:   1. I have reviewed this report on Form N-Q of Value Line Centurion Fund, Inc.   2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report

 
VALUE LINE CENTURION FUND INC Form N-Q

2015-12-01 sec.gov
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549   FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY   Investment Company Act file Number 811-03835   Value Line Centurion Fund, Inc. (Exact name of registrant as specified in charter)   7 Times Square, New York, NY 10036   Mitchell E. Appel (Name and address of agent for service)   Registrant’s telephone number, including area code: 212-907-1900   Date of fiscal year end: Decembe

 
Value Line Premier Growth Fund, Inc. Form EX-99.CERT

2015-12-01 sec.gov
    Exhibit 99.CERT    CERTIFICATIONS   I, Mitchell E. Appel, President of Value Line Premier Growth Fund, Inc. certify that:   1. I have reviewed this report on Form N-Q of Value Line Premier Growth Fund, Inc.   2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered b

 
Value Line Premier Growth Fund, Inc. Form N-Q

2015-12-01 sec.gov
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549   FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY   Investment Company Act file Number 811-02278   The Value Line Premier Growth Fund, Inc. (Exact name of registrant as specified in charter)   7 Times Square, New York, NY 10036   Mitchell E. Appel (Name and address of agent for service)   Registrant’s telephone number, including area code: 212-907-1900   Date of fiscal year end

 
Value Line Mid Cap Focused Fund, Inc. Form EX-99.CERT

2015-12-01 sec.gov
  Exhibit 99.CERT   CERTIFICATIONS   I, Mitchell E. Appel, President of Value Line Mid Cap Focused Fund, Inc. certify that:   1. I have reviewed this report on Form N-Q of Value Line Mid Cap Focused Fund, Inc.   2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by

 
Value Line Mid Cap Focused Fund, Inc. Form N-Q

2015-12-01 sec.gov
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549   FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY   Investment Company Act file Number 811-02265   The Value Line Mid Cap Focused Fund, Inc. (Exact name of registrant as specified in charter)   7 Times Square, New York, NY 10036   Mitchell E. Appel (Name and address of agent for service)   Registrant’s telephone number, including area code: 212-907-1900   Date of fiscal year en

 
NUVEEN INVESTMENT TRUST II Form EX-99.CERT

2015-11-30 sec.gov
Certifications CERTIFICATIONS I, Gifford R. Zimmerman, certify that:   1. I have reviewed this report on Form N-Q of Nuveen Investment Trust II;   2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;   3.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...